Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02018315 · ClinicalTrials.gov registry record · Phase 1
Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)
A Phase 1 study, sponsored by Juan Pascual.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02018315: Completed Phase 1 study, sponsored by Juan Pascual.
NCT02018315 is a Phase 1 study that has completed, run by Juan Pascual. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02018315, a Phase 1 study, has completed, sponsored by Juan Pascual.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine if an alternative energy source will impact brain metabolism in a disorder characterized by glucose metabolism failure in the brain. The central hypothesis tested in this investigation is whether circumventing impaired glucose metabolism is feasible, safe and potentially promising by supplying anaplerotic precursors through metabolism of odd-carbon fatty acids that can enter the citric acid cycle (CAC) through alternative metabolic pathways.
Primary Outcome
Visual analysis of EEG recording to determine the fraction of spike-range within the area of recording.
Interventions
- DRUG Triheptanoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
What the finished NCT02018315 record still lists
NCT02018315 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which Triheptanoin is the first listed.
NCT02018315 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02018315 about?
NCT02018315 is a clinical study titled "Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)". The purpose of this trial is to determine if an alternative energy source will impact brain metabolism in a disorder characterized by glucose metabolism failure in the brain. The central hypothesis tested in this investigation is whether circumventing impaired glucose metabolism is feasible, safe a...
What is the current status of trial NCT02018315?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2012-01. Estimated completion is 2014-03.
What interventions are being tested in trial NCT02018315?
The interventions under investigation include: Triheptanoin (DRUG).
Who is sponsoring clinical trial NCT02018315?
This trial is sponsored by Juan Pascual, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02018315's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia